Lo scavo archeologico di Campo della Fiera ad Orvieto / The archeological site of Campo della Fiera in Orvieto

Tra le attività promosse dal Dipartimento di Beni Culturali figura la partecipazione ad un importante progetto di ricerca archeologica che prevede campagne di scavo annuali ad Orvieto e condotte su concessione ministeriale dall’Università degli Studi di Perugia in collaborazione con l’Università degli Studi di Macerata e dirette dalla Prof.ssa Simonetta Stopponi; alla ricerca prendono parte anche studenti e laureandi dei corsi in Conservazione e Gestione dei Beni Culturali. Le indagini si svolgono grazie al sostegno finanziario dalla Fondazione Cassa di Risparmio di Orvieto; nel 2009 e nel 2010 sono statielargiti contributi anche dal Dipartimento di Beni Culturali.From 2000 on Campo della Fiera at Orvieto (Velzna in Etruscan language and Volsinii in Latin language) annual excavations directed by Prof. Simonetta Stopponi of the University of Perugia are held (in collaboration with the Department of Cultural Heritage of University of Macerata) to explore the federal sanctuary of Etruscans, where the delegates of 12 Etruscans people were known to hold their reunions and that epigraphic and topographic evidences indicate to search at Orvieto

Campo della Fiera

2La ricerca è stata avviata (nel 2000) per verificare l' esistenza, ormai pressochè accertata, del santuario federale degli Etruschi, il fanum Voltumnae delle fonti letterarie. Lo scavo, i cui risultati sono stati accolti con ampio consenso dalla comunità scientifica, copre finora una superficie di oltre 3 ha.noneS. Stopponi; C. GiontellaStopponi, Simonetta; Giontella, Claudi

Orvieto, Campo della Fiera

La ricerca \ue8 stata avviata (nel 2000) per verificare l' esistenza, ormai pressoch\ue8 accertata, del santuario federale degli Etruschi, il fanum Voltumnae delle fonti letterarie. Lo scavo, i cui risultati sono stati accolti con ampio consenso dalla comunit\ue0 scientifica, occupa, fino ad oggi, una superficie di oltre 3 ha. URL

Central Systolic Blood Pressure Is Associated With Early Vascular Damage in Children and Adolescents With Type 1 Diabetes

Objective of the study: This study aimed to test the effect of multiple cardiovascular risk factors on subclinical indices of atherosclerosis in children and adolescents with type 1 diabetes (T1D).Methods: Carotid intima-media thickness (cIMT), carotid distensibility coefficient (cDC), and carotid-femoral pulse wave velocity (PWV) were measured in children and adolescents with T1D, in a follow-up at the outpatient clinics of Verona. Blood pressure (BP; both central and peripheral), metabolic and other cardiovascular risk factors were evaluated in multivariate linear regressions to assess the association with the measured indices of subclinical vascular damage.Results: One hundred and twenty-six children and adolescents were included. cIMT was above the 95th percentile for age and height in 60.8% of the population, whereas 26% of the sample had cDC impairment (less than the 5th percentile) and 4.8% had an elevated PWV. Independent determinants of cIMT according to the regression models were only gender type of glucose monitoring and central systolic BP (cSBP). PWV was associated with age, sex, heart rate, and cSBP; cDC with age and both cSBP and, alternatively, peripheral BP (pBP). Neither pBP nor any of the tested metabolic parameters, including glycated hemoglobin, was associated with PWV and cIMT.Conclusions: A high proportion of early vascular damage, especially an increased cIMT, is present in children and adolescents with T1D in whom cSBP seems to be a common determinant. In children and adolescents with T1DM, a special focus should be on hemodynamic risk factors beyond metabolic ones

Markers of subclinical vascular damage in young adults with type 1 diabetes mellitus: the role of central blood pressure

Introduction: Type 1 diabetes mellitus (T1D) is a chronic disease leading to cardiovascular complications that can be diagnosed early as subclinical vascular damage. To prevent such damage, it is important to increase knowledge of the effects of the different cardiovascular risk factors in patients with T1D. The aim of our study was to assess possible associations between markers of subclinical arterial damage and traditional cardiovascular risk factors, with a special focus on peripheral blood pressure and central blood pressure (cBP), in a sample of young adults with T1D. Patients and methods: The study included 172 T1D patients (mean age 24.7 +/- 8.7 years, duration of T1D 13.5 +/- 9.6 years). Pulse wave velocity (PWV), pulse wave analysis and cBP were assessed by tonometry (SphygmoCor Xcel). Carotid intima-media thickness (cIMT) and carotid distensibility coefficient (cDC) were assessed by high-resolution echo-Doppler analysis and further examined with dedicated hardware. Results: Seventeen patients (10.1%) were classified as hypertensive by office peripheral blood pressure, and 48 patients (27.9%) were classified as hypertensive by cBP. One hundred sixteen patients (68.8%) had cDC under the range of normality, one patient had a PWV (0.6%) above 10 m/s, and no patients had a cIMT above 0.9 mm. In multivariable analysis, central SBP, but not metabolic parameters, remained associated with all the markers of subclinical arterial damage [cIMT (beta = 0.288 +/- 0.001; P < 0.001), PWV (beta = 0.374 +/- 0.007; P < 0.001), cDC (beta = -0.149 +/- 0.055; P = 0.029)]. Conclusion: The independent association between cBP and markers of subclinical vascular damage underlines the importance of haemodynamic factors in the development of early signs of macrovascular disease in T1D patients. Further studies are warranted to better define the role of cBP to stratify cardiovascular risk, to individualize the need for follow-up and to tailor preventive strategies in T1D patients

Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib

Background: Gastric pH changes by proton-pump-inhibitors (PPIs) were found to affect progression-free survival (PFS) in metastatic breast cancer (mBC) patients treated with palbociclib. The current study was aimed at investigating whether the same effect could occur in patients treated with ribociclib. Patients and methods: Patients with hormone-positive/HER-2-negative mBC candidates for first-line treatment with ribociclib were enrolled in this retrospective-cohort study. Patients were classified as "no concomitant PPIs" or "concomitant PPIs"; PPI administration covered the entire or not less than 2/3 of treatment with ribociclib. All clinical interventions were made according to clinical practice. Results: A total of 128 patients were consecutively enrolled in the study; 78 belonged to the "no concomitant PPIs" group and 50 to the "concomitant PPIs" group. One hundred and six patients were endocrine-sensitive and received ribociclib and letrozole, while 22 were endocrine-resistant and were treated with ribociclib and ful-vestrant. The most prescribed PPI was lansoprazole. According to PFS, patients taking PPIs had a PFS almost superimposable to those assuming ribociclib and endocrine therapy alone (35.3 vs. 49.2 months, p = 0.594). No difference in PFS was observed in estrogen-sensitive or estrogen-resistant mBC in the presence or absence of concomitant PPI treatment (p = 0.852). No correlation with adverse events was found including grade>2 he-matological toxicities. Conclusions: The present study supports the hypothesis that the concomitant use of PPIs does not compromise the efficacy of ribociclib in a real-life setting